Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Promis Neurosciences specializes in developing antibody therapies targeting misfolded proteins involved in neurodegenerative diseases such as Alzheimer's, ALS, Parkinson's, and tauopathies. Utilizing proprietary computational platforms, it identifies disease-specific epitopes to generate highly selective monoclonal antibodies. Its pipeline includes candidates for Alzheimer’s disease, ALS, multiple system atrophy, and synucleinopathies, aiming to inhibit toxic protein propagation, reduce neurodegeneration, and improve patient outcomes through innovative biologic therapeutics.
This description was generated via AI from an annual report. Updated about 1 year ago.